Researchers found that administering hydroxyurea to patients with severe forms of beta-thalassemia boosted hemoglobin levels and enabled five patients to stop undergoing transfusions. The treatment also improved quality of life for the children, who reported feeling better and more active.
A recent study confirms oxaliplatin's safety in treating advanced colorectal cancer, with low rates of high-grade gastrointestinal side effects. The treatment regimen, combined with fluorouracil and leucovorin, showed improved results in patients who had previously failed first-line chemotherapy.
Two studies suggest that regular use of ibuprofen and aspirin inhibits breast cancer formation, while a low-dose tamoxifen regimen may effectively treat breast cancer with fewer side effects. Another study found that a combination of low-dose COX-2 inhibitors and fish oil may reduce colon cancer risk.
Researchers developed a gene therapy technique that uses an oncoretrovirus to transfer MGMT into normal bone marrow cells, allowing for the enrichment of healthy cells. The treatment showed promising results in mice with beta-thalassemia, achieving successful in vivo selection in 66% of cases.
A phase 2 clinical trial found that bortezomib responded positively in 193 relapsed patients, including seven with undetectable myeloma protein and 12 with detectable protein only with immunofixation. The results confirmed significant clinical benefits from therapy.
Researchers found that patients with a negative pretransplantation scan had a favorable outcome, with 25 still in complete remission after a median follow-up of 1,510 days. In contrast, patients with a positive scan relapsed more frequently, highlighting the potential for [F]FDG-PET to identify nonresponders.
A study by Dr. Pio and colleagues found that FLT-PET imaging outperforms FDG-PET in predicting tumor response to chemotherapy in breast cancer patients. The researchers compared the two imaging modalities in 11 newly diagnosed patients, taking scans before treatment began, after the first dose, and following the final cycle.
The American Society of Hematology's Journal of Blood is the most cited peer-reviewed publication in the field, featuring latest research on blood disorders. New articles will be made available online about three months ahead of print.
The study found that BAC proliferation correlated with HER2 but not EGFR expression, suggesting a potential role for combination therapies. Researchers hope to launch a clinical trial of HER2- and EGFR-blocker combination therapy in the treatment of BAC.
The Ireland Cancer Center's Phase I and II trials report remarkable responses to new therapies for skin lymphoma, multiple myeloma, and solid tumors. These innovative treatments overcome common complications like kidney and liver damage, offering hope to patients with limited treatment options.
The GELA study reveals that MabThera plus CHOP improves three-year event-free survival by 18% and overall survival by 11%, with no increased toxicity. This breakthrough treatment offers a potential cure for aggressive NHL, which affects 55% of the 1.5 million people worldwide suffering from non-Hodgkin's lymphoma.
Researchers have found an increased risk of nonmelanoma skin cancer among childhood cancer survivors, with the University of Minnesota presenting their findings at the American Society of Clinical Oncology meeting. The study's lead author notes that further research is needed to determine why this association exists.
A new study found that the California law SB 37 has eliminated a major barrier to cancer clinical trial participation, with no patients citing insurance limitations as a reason. Participation rates have increased from 51% to 69%, but further awareness campaigns are needed to raise rates more dramatically.
Research reveals that survivors of childhood cancer are experiencing significant sleep disturbances even years after completing treatment. The University of Minnesota study aims to investigate the causes and effects of these issues.
Dr. Coughlin's research involves manipulating immune cells to recognize and kill tumors and viruses, holding promise for cancer treatment and vaccine delivery in children. She will present her work at the Society for Pediatric Research Annual Meeting and receive an award recognizing her leadership and contributions to pediatric research.
Scientists identify key amino acid sequence responsible for activating GPIIb-IIIa molecule, a crucial component of platelet function. This discovery provides new insights into how integrins on cells throughout the body may function.
Researchers identified 124 genes whose changes in expression differed depending on the treatment regimen, providing new clues on how medications work and how cancer cells protect themselves. The study's findings will help design more rational and effective ways to use drugs for deadly childhood leukemia.
The study identified a new gene associated with breast cancer, C35, which is over-expressed in 65% of breast cancers. Researchers believe that traditional treatment methods alone will not be effective against C35 positive breast cancer and are exploring a two-pronged approach for treatment.
Researchers at Boston Children's Hospital found that providing extra nitric oxide through inhalation may reverse or stop vaso-occlusive crisis symptoms. The treatment reduced pain scores and morphine use in patients with severe sickle cell disease, warranting further investigation.
Researchers have discovered a new six-drug chemotherapy regimen that significantly improves the overall survival rate of Ewing's sarcoma patients to 72% without metastases. The treatment has become routine care for patients with localized disease and has marked a substantial improvement in survival rates.
A newly discovered cellular process allows cells to initiate a series of events that halt the growth of damaged cells and help them survive. The activation of ATM, an enzyme that responds to DNA damage, enables cells to better respond to cancer-causing mutations and environmental toxins.
Researchers have discovered that combining Avastin with chemotherapy provides superior treatment for advanced colorectal cancer, increasing median survival by 8.3 months and response rates. The study's findings suggest a more effective and less toxic option for patients with this devastating form of cancer.
Researchers at Dana-Farber Cancer Institute identified a gene signature that distinguishes leukemia patients who can be cured with intensive chemotherapy from those who require bone marrow transplantation. Patients with high HOX11 expression survived for three years and were most likely cured, while those without it had poorer outcomes.
A new 'designer' drug has shown activity in treating acute myeloid leukemia (AML), with 13 of 15 patients experiencing reductions in abnormal white blood cell counts. The experimental compound targets a specific genetic flaw, offering a more targeted approach to conventional chemotherapy drugs.
Researchers at Dana-Farber Cancer Institute have found a promising new treatment for patients receiving stem cell transplants. The combination therapy of sirolimus and tacrolimus reduced the risk of GVHD to 13%, compared to 30% in normal cases.
New research from University of Minnesota presents promising findings on unrelated donor transplants, including a study showing improved survival rates and quality of life for leukemia/lymphoma patients. Another study explores the use of bone marrow-derived stem cells to treat Parkinson's disease.
Results from THRIVE III study demonstrate that oral EXANTA is effective in preventing recurrence of VTE events by 84% compared to placebo. The data also show no significant increase in total bleeding events for EXANTA.
The grant will support five local projects focusing on stem cell transplantation, pneumococcal infection, combination drug therapy, gene therapy, and molecular biology of hemoglobin development. St. Jude sickle cell patients will have more opportunities for new therapies and participation in groundbreaking clinical trials.
A study published in Immunity reveals that the MEF protein plays a critical role in the development and function of natural killer cells, which can recognize and kill cancer cells. The findings provide a new target for therapeutic interventions, potentially improving bone marrow transplant strategies.
A new clinical trial is investigating the combination of high-dose calcitriol and docetaxel in treating advanced prostate cancer, with the goal of reducing PSA levels by 50% or more. The study builds on promising preliminary results from a previous Oregon Health & Science University trial.
Researchers develop novel approach to treat thalassemias by blocking aberrant RNA splicing. The new virus effectively repairs existing RNA, restoring correct hemoglobin production and offering a lifeline for patients.
The primer series provides a historical background of genetics and the sequencing of the human genome, as well as principles and methods in molecular biology. The authors highlight the potential benefits of the genomic revolution in understanding diseases such as cancer, heart disease, and Alzheimer's disease.
A study by University of Minnesota researchers found that morphine activates the MAPK signaling pathway in human endothelial cells, promoting angiogenesis and tumor growth. The findings could lead to new treatments for managing cancer pain while minimizing tumor growth.
Researchers discover that a platelet molecule called phosphatidylserine plays a key role in activating the final step of blood coagulation. The finding could lead to new treatments for clotting disorders, such as heart attacks and strokes.
Dr. Katherine High, a leading gene therapy researcher, has been chosen by the Howard Hughes Medical Institute for her groundbreaking work on treating hemophilia B. Her research holds promise for delivering therapeutic genes directly into patients' cells to improve blood clotting and quality of life.
A study by Philip Breitfeld shows that initial hospital treatment costs can top $75,000 per child, but the average cost per year of life saved is just $2,700. Insurers lack access to data to justify spending on curative cancer therapies, leading to denied payments for high-priced procedures.
Decitabine has been shown to be effective in treating patients who don't respond to traditional treatment, reducing symptoms and improving quality of life. The study found that decitabine works by increasing fetal hemoglobin production, which can help alleviate the severity of sickle cell symptoms.
Researchers discovered PRDX3, a key powerhouse enzyme, plays a crucial role in controlling tumor growth. By manipulating PRDX3 activation, tumors can be halted or accelerated. Understanding this pathway could lead to new cancer treatments.
A new combination of MabThera and standard chemotherapy has shown a significant increase in overall survival rate and complete remission rates in patients with aggressive non-Hodgkin's lymphoma. This treatment offers hope for improved outcomes in this increasingly common form of blood cancer.
Researchers at Vanderbilt University Medical Center found that combining Herceptin with Iressa reduces tumor cell death and tumor size in HER2-overexpressing breast cancers. The clinical trial will enroll 150 patients and aims to shrink tumors with minimal side effects.
Researchers found that the MabThera plus CHOP combination significantly improves overall survival for patients with aggressive non-Hodgkin's lymphoma, with a 70% survival rate after 26 months. The treatment is also effective in treating indolent NHL, with up to 55% of patients remaining in remission at four years.
A two-step approach combining high-dose chemotherapy and autologous stem-cell rescue with mini-transplantation from a sibling significantly reduces transplant-related complications and increases survival rates for patients with advanced-stage multiple myeloma. The procedure results in mild to moderate treatment-related toxicities and a...
Dr. Scott Cameron, a renowned pediatric oncologist and molecular biologist, will lead research on cell growth and cancer at UT Southwestern Medical Center. The Children's Cancer Fund provided a $525,000 grant to support his four-year research program.
Arsenic inhibits transcription of the hTERT gene, which in turn inhibits telomerase, causing genetic instability that may lead to cancer in healthy cells. The study's findings also have implications for developing more effective chemotherapy treatments for leukemia.
Researchers found that small doses of suramin enhanced chemotherapy effectiveness in treating advanced stage IIIB/IV lung cancer. The tumors halved in seven patients and didn't progress in eight, showing a potential treatment option for patients with metastatic lung cancer.
A study of 13 HIV-positive men found that those with high levels of autonomic nervous system activity responded less well to antiretroviral treatment, with some experiencing no immune recovery. Stress accelerates AIDS progression by increasing viral replication and making it harder for the body to fight off the infection.
A unique gene has been identified as a regulator of stem cell growth, suggesting that embryonic and adult stem cells share key genes and properties. This discovery could lead to the development of new therapies for cancer patients in need of stem cell transplants.
Researchers have discovered a new mechanism that triggers blood cell adhesion in sickle cell disease, with P-selectin playing a key role. Inhibiting P-selectin has shown promise in reducing adhesion and potentially preventing pain crises and organ failure.
A clinical study found that children with severe hemophilia have a high risk of developing deep venous thrombosis linked to long-term catheter implants. Eight out of 15 boys in the study developed blood clots in the veins near their hearts.
Researchers at University of Wisconsin-Madison successfully directed undifferentiated human embryonic stem cells to become primitive types of blood cells, which later develop into mature blood cells. This breakthrough technology holds promise for creating novel sources of blood cells for transfusion and transplant therapies.
PS-341, a proteasome inhibitor, has shown promising results in treating multiple myeloma and non-Hodgkin's lymphoma. The Phase I clinical trial found one complete response and several partial responses among patients, indicating the drug's potential as a treatment option.
The Indiana Genomics Initiative, backed by a $105 million grant from Lilly Endowment, aims to advance educational opportunities, genomics, and bioinformatics research. The project will create a world-class biomedical enterprise at IU, capitalizing on existing resources and expertise in informatics.
Two pivotal trials of Zevalin radioimmunotherapy show overall response rates of 80% and 74%, with patients achieving complete responses to therapy. Toxicity was primarily hematologic, transient and reversible.
A new trial found that a radioactive compound called MIBG can not only image but also help kill neuroblastoma tumors. In the Phase I trial, 11 children with advanced neuroblastoma had positive responses and few side effects when treated with MIBG combined with chemotherapy and bone marrow transplant.
Researchers have developed a new screening process to detect human parvovirus B19 in blood plasma, ensuring its safety for transfusions. The discovery has already led to improvements in plasma processing and the voluntary recall of contaminated lots.
Researchers at Fred Hutchinson Cancer Center have shown promising results with a new antibody treatment, Nuvion, in patients with severe graft versus host disease. The study found that Nuvion was well-tolerated and achieved complete responses in six of nine patients who received a single dose.
A study at the American Society of Hematology Meeting found that patients with acute myeloid leukemia who achieve remission with Mylotarg have prolonged disease-free survival following stem cell transplantation. Researchers also observed fewer complications from bone marrow transplants compared to traditional treatment.
A Phase III study found significant improvements in overall survival, disease-free status, and complete remission rates for patients with aggressive non-Hodgkin's lymphoma treated with MabThera and CHOP chemotherapy. Survival at 1-year was 83% for the rituximab combination therapy group compared to 68% for those receiving CHOP alone.
Phase II studies indicate that Mylovenge causes regression or stabilization in over 30% of patients with multiple myeloma and amyloidosis, with some benefits lasting up to 18 months. The vaccine stimulates the immune system to recognize and destroy cancer cells.
Researchers at UIC College of Medicine are developing a powerful new prenatal diagnostic technique to detect genetic abnormalities in fetal blood cells. The technique, using fluorescent in-situ hybridization (FISH), will identify defects in individual genes and could potentially be used by all women who wish to undergo screening.